InnoSkel
French tech company | Builders Republic
About
Platform biotech developing gene therapies for rare skeletal disorders caused by type II collagen mutations — from spondyloepiphyseal dysplasia congenita (SEDc) to other collagenopathies — using proprietary gene therapy assets advancing through observational studies and regulatory pathways (UK MHRA Innovation Passport).
Key facts
- Status
- Morte
- Sectors
- Healthcare & Life Sciences
- Latest stage
- Series A
- Founded
- 2020
- City
- BIOT
- Region
- Provence-Alpes-Côte d’Azur
- Tracked rounds
- 1
- Amount raised
- 20 M€ raised since 2020
Funding rounds
- Series A — 2020
Investors
- Jeito Capital
- Turenne Capital
- Vida Ventures